Related Experiment Videos
Preemptive oral treatment with sumatriptan during a cluster period
Headache
|November 1, 1995
Summary
Preemptive oral sumatriptan (100 mg tid) for seven days did not significantly reduce cluster headache attack frequency or severity. The treatment was safe and well-tolerated, showing no increased adverse events.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Cluster headache is a debilitating neurological disorder characterized by severe, unilateral head pain.
- Current prophylactic treatments for cluster headache have limitations, necessitating exploration of alternative strategies.
Purpose of the Study:
- To evaluate the efficacy of preemptive oral sumatriptan in reducing the frequency and severity of cluster headache attacks.
- To assess the safety and tolerability of a 7-day course of preemptive oral sumatriptan.
Main Methods:
- A multinational, multicenter, randomized, double-blind, placebo-controlled trial involving 169 patients with cluster headache.
- Patients received oral sumatriptan (100 mg tid) or placebo for 7 days, with rescue medication available for attacks.
- Attack frequency, severity, and adverse events were recorded in patient diaries.
Main Results:
- Preemptive oral sumatriptan did not significantly decrease the number or severity of cluster headache attacks during the 7-day treatment period.
- The safety and tolerability profile of oral sumatriptan was consistent with previous reports, with no increased adverse events observed.
Conclusions:
- A 7-day preemptive course of oral sumatriptan is not effective in managing acute cluster headache periods.
- Further research may be needed to explore different dosing strategies or patient populations for sumatriptan's prophylactic use in cluster headache.